Market News / Story
Quantum BioPharma Ltd. (NASDAQ: QNTM) Enters Study Start-Up Agreement for Lucid-MS Phase 2 Trial
FinanceWire ·
FinanceWire reports: Pune, India, October 6th, 2026, FinanceWire This is a paid advertisement. Quantum BioPharma Ltd. (FRA: 0K91) has entered into a Study Start-Up Agreement ("SUA") with the clinical research business of Thermo Fisher Scientific. The agreement covers implementation of Quantum's Phase 2 clinical trial of Lucid-21-302 ("Lucid-MS") for multiple sclerosis ("MS"). The company said the contract is an important milestone in the clinical development of Lucid-MS. It also marks the…